Skip to main content

Table 3 Average hemoglobin changes from baseline during weeks 5–13 (or last assessment): intent-to-treat population.

From: Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy

C.E.R.A. dose group, μg/kg

n

Least squares mean (95% CI)* Hb change (g/dL)

QW

  

0.7

31

-0.24 (-0.79 to +0.31)

1.4

35

0.02 (-0.49 to +0.54)

2.1

34

0.40 (-0.12 to +0.93)

Q3W

  

2.1

31

-0.16 (-0.75 to +0.42)

4.2

36

0.19 (-0.35 to +0.73)

6.3

33

0.66 (0.09 to +1.22)

  1. C.E.R.A.: Continuous Erythropoietin Receptor Activator.
  2. Hb: hemoglobin.
  3. QW: once weekly.
  4. Q3W: once every 3 weeks.
  5. *Derived from analysis of covariance including dose group (QW and Q3W separately) as a fixed factor and the baseline value as a covariate in the model.
  6. CI: confidence interval.
Back to article page

Trials

ISSN: 1745-6215